Heron Therapeutics (HRTX) Net Cash Flow (QoQ) (2010 - 2026)
Heron Therapeutics (HRTX) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -113.28% |
| Mar 31, 2026 | 82.46% |
| Dec 31, 2025 | -154.31% |
| Sep 30, 2025 | 1,064.48% |
| Jun 30, 2025 | 57.86% |
| Mar 31, 2025 | -10,809.84% |
| Dec 31, 2024 | -99.17% |
| Sep 30, 2024 | 456.35% |
| Jun 30, 2024 | 74.91% |
| Mar 31, 2024 | -33.08% |
| Dec 31, 2023 | -128.89% |
| Sep 30, 2023 | 257.01% |
| Jun 30, 2023 | -216.22% |
| Mar 31, 2023 | 133.43% |
| Dec 31, 2022 | -2,017.66% |
| Sep 30, 2022 | 122.03% |
| Jun 30, 2022 | 75.31% |
| Mar 31, 2022 | 51.28% |
| Dec 31, 2021 | -118.43% |
| Sep 30, 2021 | -124.04% |